TIP (paclitaxel + ifosfamide + cisplatin, penile SCC)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-PACLITAXEL` `DRUG-IFOSFAMIDE` `DRUG-CISPLATIN`

ID	`REG-TIP-PENILE`
Type	Regimen
Status	reviewed 2026-07-11 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-EAU-PENILE-2024`

Notes

STUB. TIP composition and general dosing convention (paclitaxel d1; ifosfamide+cisplatin d1-3 with mandatory mesna; q21d) mirrors the EAU-guideline TIP regimen for penile SCC, and is distinct in schedule from the germ-cell-tumor salvage TIP already in this KB (REG-TIP-GCT-SALVAGE — 24h paclitaxel infusion, ifosfamide/cisplatin days 2-5). Drafted pending clinical co-lead signoff (CHARTER §6.1; dev-mode-exempted for draft merge). No phase III RCT exists in this rare disease — evidence base is small phase II / retrospective series; EAU guidelines list TIP as an option alongside cisplatin+5-FU, and additionally as neoadjuvant therapy before consolidative nodal surgery in regionally advanced disease.

Used By

Indication

IND-PENILE-SCC-METASTATIC-1L-CISPLATIN-5FU - IND-PENILE-SCC-METASTATIC-1L-CISPLATIN-5FU
IND-PENILE-SCC-METASTATIC-1L-TIP - IND-PENILE-SCC-METASTATIC-1L-TIP

Regimen

REG-CISPLATIN-5FU-PENILE - Cisplatin + 5-fluorouracil (metastatic penile SCC, 1L)